title: Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema.
authors: Ehsan
authors: E
authors: Rahimy
authors: David
authors: D
authors: Sarraf
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy / Q000601:surgery; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy / Q000601:surgery; D004965:Estrogen Antagonists / Q000009:adverse effects*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D012164:Retinal Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D013629:Tamoxifen / Q000009:adverse effects*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004965:Estrogen Antagonists; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D013629:Tamoxifen; D000068258:Bevacizumab